Abstract
There are pharmacodynamics, pharmacokinetics, clinical aspects of the use of bismuth tripotassium dicitrate and comparative analysis of the physicochemical and structural properties of tableted forms of preparations containing bismuth tripotassium dicitrate - the original drug De-Nol® (Astellas) and the generic drug Ulcavis® (KRKA) in the article. Demonstrated similar physical and chemical properties, the similarity of the disintegration rate of the two tablets of bismuth tripotassium dicitrate suggests a similar clinical effectiveness of the reproduced and reference drug.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
